Prosecution Insights
Last updated: April 19, 2026

Examiner: VASSELL, MEREDITH ABBOTT

Tech Center 1600 • Art Units: 1624 1671 1687

This examiner grants 25% of resolved cases

Performance Statistics

25.0%
Allow Rate
-35.0% vs TC avg
92
Total Applications
+42.7%
Interview Lift
2011
Avg Prosecution Days
Based on 56 resolved cases, 2023–2026

Rejection Statute Breakdown

29.6%
§101 Eligibility
4.3%
§102 Novelty
28.1%
§103 Obviousness
27.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17162897 SIGNIFICANCE MODELING OF CLONAL-LEVEL ABSENCE OF TARGET VARIANTS Non-Final OA GUARDANT HEALTH, INC.
16560752 METHODS AND SYSTEMS FOR DETECTING ALLELIC IMBALANCE IN CELL-FREE NUCLEIC ACID SAMPLES Non-Final OA GUARDANT HEALTH, INC.
19231368 COMPUTATIONAL FRAMEWORK FOR ENHANCING A SIGNAL-TO-NOISE RATIO (SNR) IN PROCESSING NOISY READ SIGNALS Final Rejection The Broad Institute, Inc.
18243623 HEALTH-RELATED SIGNALING VIA WEARABLE ITEMS Non-Final OA Biolinq Incorporated
16827366 HEALTH-RELATED SIGNALING VIA WEARABLE ITEMS Non-Final OA Biolinq Incorporated
16816732 BIOLOGICAL REACTION INFORMATION PROCESSING SYSTEM AND BIOLOGICAL REACTION INFORMATION PROCESSING METHOD Non-Final OA Hitachi, Ltd.
19226403 METHOD FOR GENERATION OF CHEMICAL DERIVATIVES AGAINST TARGET PROTEIN TO BUILD AI DRUG PLATFORM Final Rejection SYNTEKABIO, INC.
19219826 ASSESSING RISK FOR MULTIPLE MYELOMA PRECURSOR DISEASE PROGRESSION Final Rejection Dana-Farber Cancer Institute, Inc.
19098448 IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA Non-Final OA Dana-Farber Cancer Institute, Inc.
17250389 BIOMARKERS AND TEST MODELS FOR CHRONIC KIDNEY DISEASE Final Rejection MARS, INCORPORATED
17711617 GENERATING MINORITY-CLASS EXAMPLES FOR TRAINING DATA Non-Final OA NEC Laboratories America, Inc.
17766008 PROCESS AND DEVICE FOR DETERMINING A RESPIRATORY AND/OR CARDIOGENIC SIGNAL Non-Final OA Drägerwerk AG & Co. KGaA
17436817 DATA ANALYSIS METHOD, DATA ANALYSIS SYSTEM, AND COMPUTER Final Rejection HITACHI HIGH-TECH CORPORATION
17636272 SINGLE-CELL MODELING OF CLINICAL DATA TO DETERMINE RED BLOOD CELL REGULATION Non-Final OA The General Hospital Corporation
17221430 SYSTEM AND METHOD FOR GENERATING A TOXICOLOGICAL AILMENT NOURISHMENT PROGRAM Non-Final OA KPN INNOVATIONS, LLC.
18273161 COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS Non-Final OA CEDARS-SINAI MEDICAL CENTER
17585358 ECG SEARCH AND INTERPRETATION BASED ON A DUAL ECG AND TEXT EMBEDDING MODEL Final Rejection AliveCor, Inc.
16417336 INFERRING SELECTION IN WHITE BLOOD CELL MATCHED CELL-FREE DNA VARIANTS AND/OR IN RNA VARIANTS Final Rejection Grail, LLC
17632658 SYSTEMS AND METHODS FOR DISEASE AND TRAIT PREDICTION THROUGH GENOMIC ANALYSIS Non-Final OA SALK INSTITUTE FOR BIOLOGICAL STUDIES
16329183 CONTROLLING AND MONITORING A PROCESS TO PRODUCE A CHEMICAL, PHARMACEUTICAL OR BIOTECHNOLOGICAL PRODUCT Non-Final OA Sartorius Stedim Biotech GmbH
17777100 METHOD FOR DETECTING LUNG CANCER Non-Final OA Sierra Medical Ltd
17555968 METHOD AND SYSTEM FOR OBTAINING, CONTROLLING, ACCESSING AND/OR DISPLAYING PERSONAL GENETIC IDENTIFICATION INFORMATION Final Rejection STR-ID, INC.
17207485 PREDICTING EFFICACY OF PREVENTATIVE MEASURES TO MITIGATE SPREAD OF A PATHOGEN AND ILLNESSES CAUSED THEREFROM USING MACHINE LEARNING MODELS Final Rejection General Genomics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month